JPWO2021071788A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021071788A5 JPWO2021071788A5 JP2022520976A JP2022520976A JPWO2021071788A5 JP WO2021071788 A5 JPWO2021071788 A5 JP WO2021071788A5 JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022520976 A JP2022520976 A JP 2022520976A JP WO2021071788 A5 JPWO2021071788 A5 JP WO2021071788A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- oligonucleotides
- c9orf72
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 27
- 108091034117 Oligonucleotide Proteins 0.000 claims 24
- 101150014718 C9orf72 gene Proteins 0.000 claims 15
- 102000043334 C9orf72 Human genes 0.000 claims 14
- 108700030955 C9orf72 Proteins 0.000 claims 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000000295 complement effect Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962911340P | 2019-10-06 | 2019-10-06 | |
US62/911,340 | 2019-10-06 | ||
US202062983736P | 2020-03-01 | 2020-03-01 | |
US62/983,736 | 2020-03-01 | ||
PCT/US2020/032244 WO2020227691A2 (en) | 2019-05-09 | 2020-05-08 | Oligonucleotide compositions and methods of use thereof |
USPCT/US2020/032244 | 2020-05-08 | ||
US202063069704P | 2020-08-24 | 2020-08-24 | |
US63/069,704 | 2020-08-24 | ||
PCT/US2020/054307 WO2021071788A2 (en) | 2019-10-06 | 2020-10-05 | Oligonucleotide compositions and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022550915A JP2022550915A (ja) | 2022-12-05 |
JPWO2021071788A5 true JPWO2021071788A5 (enrdf_load_stackoverflow) | 2024-01-11 |
Family
ID=75438309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022520976A Pending JP2022550915A (ja) | 2019-10-06 | 2020-10-05 | オリゴヌクレオチド組成物及びその使用方法 |
Country Status (12)
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
AU2015207773B2 (en) | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
WO2017210647A1 (en) | 2016-06-03 | 2017-12-07 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
AU2017281497B2 (en) | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
PL3507366T3 (pl) | 2016-09-01 | 2021-05-04 | Proqr Therapeutics Ii B.V. | Chemicznie modyfikowane jednoniciowe oligonukleotydy edytujące rna |
JP7296882B2 (ja) | 2016-11-23 | 2023-06-23 | ウェイブ ライフ サイエンシズ リミテッド | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
CN110997692B (zh) | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
CN111051281A (zh) | 2017-06-21 | 2020-04-21 | 波涛生命科学有限公司 | 用于合成的化合物、组合物和方法 |
KR20200035301A (ko) | 2017-08-08 | 2020-04-02 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
WO2019075357A1 (en) | 2017-10-12 | 2019-04-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
CN112218664A (zh) | 2018-05-11 | 2021-01-12 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
AR131145A1 (es) | 2022-11-24 | 2025-02-19 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria |
GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
WO2024200472A1 (en) | 2023-03-27 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2856403T3 (es) * | 2014-03-18 | 2021-09-27 | Univ Massachusetts | Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica |
RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
HUE049233T2 (hu) * | 2015-04-16 | 2020-09-28 | Ionis Pharmaceuticals Inc | C9ORF72-expresszió módosítására szolgáló készítmények |
TW201722439A (zh) * | 2015-10-09 | 2017-07-01 | 波濤生命科學有限公司 | 寡核苷酸組合物及其方法 |
US11260073B2 (en) * | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
KR20200035301A (ko) * | 2017-08-08 | 2020-04-02 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
CN114502177A (zh) * | 2019-05-09 | 2022-05-13 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
-
2020
- 2020-10-05 KR KR1020227015125A patent/KR20220070324A/ko not_active Withdrawn
- 2020-10-05 EP EP20875598.3A patent/EP4037695A4/en active Pending
- 2020-10-05 CN CN202080069266.5A patent/CN114585370A/zh active Pending
- 2020-10-05 BR BR112022006207A patent/BR112022006207A2/pt not_active Application Discontinuation
- 2020-10-05 IL IL291974A patent/IL291974A/en unknown
- 2020-10-05 MX MX2022004102A patent/MX2022004102A/es unknown
- 2020-10-05 WO PCT/US2020/054307 patent/WO2021071788A2/en not_active Application Discontinuation
- 2020-10-05 US US17/766,680 patent/US20240175016A1/en active Pending
- 2020-10-05 CA CA3156176A patent/CA3156176A1/en active Pending
- 2020-10-05 AU AU2020363344A patent/AU2020363344A1/en not_active Abandoned
- 2020-10-05 JP JP2022520976A patent/JP2022550915A/ja active Pending
- 2020-10-06 TW TW109134610A patent/TW202126810A/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2021071788A5 (enrdf_load_stackoverflow) | ||
JPWO2020227691A5 (enrdf_load_stackoverflow) | ||
JP2020534253A5 (enrdf_load_stackoverflow) | ||
JPWO2021178237A5 (enrdf_load_stackoverflow) | ||
US20230220393A1 (en) | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | |
JP2023078293A5 (enrdf_load_stackoverflow) | ||
JP2024009824A5 (enrdf_load_stackoverflow) | ||
CA3156176A1 (en) | Oligonucleotide compositions and methods of use thereof | |
CA3139513A1 (en) | Oligonucleotide compositions and methods of use thereof | |
JP2023145620A5 (enrdf_load_stackoverflow) | ||
DE60132170T2 (de) | MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN | |
CA3072076A1 (en) | Oligonucleotide compositions and methods thereof | |
JP2018525357A5 (enrdf_load_stackoverflow) | ||
JP2009532392A5 (enrdf_load_stackoverflow) | ||
CA2453301A1 (en) | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | |
JP7690979B2 (ja) | 一本鎖オリゴヌクレオチド | |
JPWO2019217784A5 (enrdf_load_stackoverflow) | ||
CA2989682A1 (en) | Oligonucleotide compositions and methods thereof | |
RU2015104762A (ru) | Хиральный контроль | |
WO1995017507A1 (en) | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE | |
JP2021500013A (ja) | B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子 | |
JP2006141402A5 (enrdf_load_stackoverflow) | ||
WO2021157730A1 (ja) | 核酸医薬とその使用 | |
EP3677680A1 (en) | Small guide antisense nucleic acid and use thereof | |
TW390884B (en) | Chirally enriched synthetic phosphonate oligomers |